Clinical Trials Browser

Phase 2 × INDUSTRY × CPX-351 × Clear all

NCT02269579 2018-03-14

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

Phase 2 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00788892 2018-01-12

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Phase 2 Completed

126 enrolled 12 charts

Other hematologic neoplasm

Disease, Leukemia, Leukemia, Myeloid, Acute

NCT02238925 2017-11-30

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Phase 2 Completed

26 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00822094 2017-11-24

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

Phase 2 Completed

126 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute